BioPharm Asia, Inc., (ticker:”BFAR”), is a Nevada corporation involved in the sale of medical products to drug stores, hospitals, neighborhood clinics, and other medicine retail outlets in the People’s Republic of China. BFAR was de-listed from the NASDAQ in June 2013 after it stopped reporting to the Securities & Exchange Commission (“SEC”).
Certain shareholders have spoken with Robert W. Seiden, Esq. in New York to represent a group of shareholders to enforce the rights of the U.S. shareholders for acts detrimental to the investors including failure to report to the SEC in order to get a possible return of capital to the investors. . .